Navigation Links
Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
Date:10/29/2007

Application of ZFN Technology in Stem Cells has Potential to Yield High

Value Research Reagents and Therapeutic Products

ST. LOUIS and RICHMOND, Calif., Oct. 29 /PRNewswire-FirstCall/ -- Sigma-Aldrich Corporation (Nasdaq: SIAL) and Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today the publication of data demonstrating the use of Sangamo's ZFP Nucleases (ZFNs) for "gene-editing" in human stem cells. This work represents a significant advance in the ability to specifically and efficiently modify the human genome in stem cells potentially enabling the efficient generation of stem cell lines for use as models of human disease for medical research and for drug testing. In addition to its use in the generation of valuable research reagents, the technology has potential in the therapeutic application of stem cells.

The work, which was carried out in the laboratory of Luigi Naldini, M.D., Ph.D. at the San Raffaele Telethon Institute for Gene Therapy, Milan, Italy, in collaboration with Sangamo scientists, was published in Nature Biotechnology as an advance online publication (http://www.nature.com/nbt/journal/vaop/ncurrent/abs/nbt1353.html).

"This is a significant advance for both research and the potential therapeutic use of stem cells," stated Dr. Naldini, a senior author of the study. "Stem cells are the body's natural resource for regeneration and re
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting
2. Sangamo BioSciences Announces Presentation of ZFP Therapeutic Data From Nerve Regeneration Program at American Society for Neural Therapy and Repair Meeting
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
5. Neurocrine Biosciences Announces New Research Studies Presented at APSS Reveal Significant Under-Diagnosis of Insomnia
6. Hana Biosciences Presents Data On Two Programs At the American Society of Clinical Oncology Annual Meeting
7. IR BioSciences Announces Promising Data from Study of Its Compound Homspera
8. Lux Biosciences Investigational Therapy for Uveitis, LX211, is Subject of Two Presentations at Key Ophthalmology Meeting, ARVO 2007
9. YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets Primary Endpoint in Patients with Post-Surgical Pain
10. Hana Biosciences Announces Data to be Presented On Talvesta (Talotrexin) for Injection at The American Association for Cancer Research Annual Meeting
11. Ace Biosciences, Ace393, the Worlds First Commercial Vaccine for Travellers Diarrhoea Caused by Campylobacter Successfully Completes Phase I Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... LAVAL, Quebec , March 27, 2015  Valeant ... announced today the closing of its previously announced registered ... States (the "Offering"). Pursuant to the Offering, ... of $199.00 per share, for aggregate gross proceeds of ... filed with the U.S. Securities and Exchange Commission a ...
(Date:3/27/2015)... March 27, 2015  RXi Pharmaceuticals Corporation ... LLC, today announced that they have entered ... novel and proprietary sd-rxRNA® technology for use ... collaboration has the potential to result in ... treatments that could be a significant step ...
(Date:3/27/2015)... 27, 2015  WebMD Health Corp. (NASDAQ: ... health information, today announced an exclusive White ... Action Plan for Combating Antibiotic-Resistant Bacteria . ... urgency and importance of addressing antibiotic-resistant bacteria ... health.    The WebMD interview, available ...
Breaking Medicine Technology:Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common Shares 2Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common Shares 3RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 2RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 3RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 4RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 5Exclusive: WebMD Interviews President Obama About Plan for Combating Antibiotic Resistance 2Exclusive: WebMD Interviews President Obama About Plan for Combating Antibiotic Resistance 3
... , , , ... leading developer of medical device technology for the safe ... new Webinar program supporting its culture of safety initiative ... "A Culture of Safety in Pharmacy: Lessons Learned," features ...
... , MOUNTAIN VIEW, Calif., Dec. 29 VIVUS, Inc. (Nasdaq: ... therapies to address unmet needs in obesity, diabetes and sexual ... been submitted to the U.S. Food and Drug Administration (FDA) ... of obesity, including weight loss and maintenance of weight loss, ...
Cached Medicine Technology:Baxa Corporation to Sponsor Free Culture of Safety Webinar 2Baxa Corporation to Sponsor Free Culture of Safety Webinar 3VIVUS Submits Qnexa(R) New Drug Application to the FDA for the Treatment of Obesity 2VIVUS Submits Qnexa(R) New Drug Application to the FDA for the Treatment of Obesity 3VIVUS Submits Qnexa(R) New Drug Application to the FDA for the Treatment of Obesity 4VIVUS Submits Qnexa(R) New Drug Application to the FDA for the Treatment of Obesity 5
(Date:3/27/2015)... 27, 2015 On February 21, ... in the Stardust Penthouse on the rooftop of ... Angeles’ leading sustainable product TV and film placement ... day-long event, which featured some of the world’s ... products and services. , “We were honored to ...
(Date:3/27/2015)... March 27, 2015 According to a ... ), the plate and screw market in Europe is ... generic plate and screw segment. Price decreases are being ... representing almost 50% of the total European trauma device ... the total market value, year after year. , ...
(Date:3/27/2015)... 2015 According to Health Day ... with Neonatal Abstinence Syndrome (NAS) are causing alarm for ... painful withdrawal process for a month of their lives- ... diarrhea, and vomiting. The condition is precipitated by drug ... addiction treatment (and employing medically assisted drug treatment) will ...
(Date:3/27/2015)... March 27, 2015 When struck with ... hard to know where to begin. The latest ... trucking accident attorney, offers accident victims a clear and ... assistance to ensure their personal injury claim is seen ... describing the first actions that should be taken immediately ...
(Date:3/27/2015)... Texas (PRWEB) March 27, 2015 ... Glutathione Industry is a professional and in-depth study ... glutathione market with a focus on the ... overview of the industry including definitions, classifications, applications ... is provided for both the international and Chinese ...
Breaking Medicine News(10 mins):Health News:Choices Recovery Releases 'Salute to the Oscars' EcoLuxe Lounge Compilation Video 2Health News:Titanium Trauma Treatment Devices in Europe Becoming More Affordable, Decreasing Market Value: Group Purchasing Further Eroding Selling Prices 2Health News:Titanium Trauma Treatment Devices in Europe Becoming More Affordable, Decreasing Market Value: Group Purchasing Further Eroding Selling Prices 3Health News:In Florida Only 10% of Pregnant Mothers Are Referred to Drug Rehab Despite Testing Positive for Narcotics 2Health News:Dax Jones Updated eBook on Trucking Accidents Offers Helpful Information to Crash Victims 2Health News:Glutathione Industry International and China Market Analysis Report 2015-2020 2Health News:Glutathione Industry International and China Market Analysis Report 2015-2020 3
... nutritional supplements ... in North ... Alliance,(CWA), experts in designing custom wellness programs for consumers and,corporations, ... announcement was made by biochemist, Lyle MacWilliam, author,of the recently ...
... many,people who have called and asked how they could help, ... with Tony Snow,s children,s education and,expenses., Jill Snow, Tony,s ... Kendall, Robbie and Kristi, as beneficiaries. Donations can,be made directly ... check,made payable to the "Tony Snow Family Trust" to:, ...
... ANGELES, July 14 The Cooperative of American,Physicians, ... exceeded 10,000 physicians., "Surpassing the 10,000 member ... CEO James L. Weidner. "The physicians who founded,CAP ... They believed that,physicians working together could find a ...
... with upbeat outlook, but same did not hold true for women ... had a lower risk of dying from heart disease turned out ... their conventional risk factors showed. , The death rate for men ... of those who listed themselves as being at average risk, said ...
... The Medical Device,Manufacturers Association (MDMA), a national trade ... the Board of Directors at the,MDMA Annual Meeting ... http://www.newscom.com/cgi-bin/prnh/20041004/MDMALOGO ), "I am honored to ... Manufacturers,Association," stated Root. "MDMA has a long history ...
... in heart and travels to the brain, heparin more risky, ... widely prescribed blood-thinning drug heparin is associated with an increased ... cardioembolic stroke, new research shows. , But another thinning ... in the same group of patients. , This finding led ...
Cached Medicine News:Health News:Vitalize(TM) Receives Top Multivitamin Rating 2Health News:Cooperative of American Physicians Membership Tops 10,000 2Health News:Optimism About Heart Risk Pays Off 2Health News:Vascular Solutions CEO Elected to MDMA Board of Directors 2Health News:Warfarin Safer Than Heparin for Some Strokes 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: